{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:18:23Z","timestamp":1778062703632,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Obstructive jaundice is a common clinical condition, often caused by malignant tumors such as hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA). Percutaneous transhepatic cholangiodrainage (PTCD) is a widely used intervention method to relieve biliary obstruction in patients with obstructive jaundice; however, the impact of PTCD on hepatitis B virus (HBV) reactivation has not been thoroughly studied. Methods: A retrospective analysis was conducted from January 2016 to December 2024 on 235 patients with obstructive jaundice who underwent PTCD. Demographic, clinical, and procedural data were collected, and multivariate logistic regression was used to identify risk factors for HBV reactivation. Additionally, Cox regression was used to evaluate the time-to-reactivation variables. Results: The HBV reactivation rate in the PTCD group was 21.7%, significantly higher than the 8.9% in the non-PTCD group. Key risk factors for HBV reactivation in the PTCD group included the absence of antiviral prophylaxis, postoperative infection, elevated preoperative HBV-DNA levels, and multiple biliary punctures. Moreover, Cox regression revealed that a lack of antiviral therapy and postoperative infection were associated with earlier HBV reactivation. Conclusions: PTCD significantly increases the risk of HBV reactivation in patients with obstructive jaundice, especially in those with high preoperative HBV-DNA levels and without antiviral prophylaxis. Early detection of HBV reactivation and the initiation of antiviral therapy are critical to improving patient outcomes. These findings underscore the need for careful monitoring of HBV status in patients undergoing PTCD.<\/jats:p>","DOI":"10.3390\/jcm15093263","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:28:23Z","timestamp":1777040903000},"page":"3263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Percutaneous Transhepatic Cholangiodrainage (PTCD)-Related Hepatitis B Virus Reactivation in Obstructive Jaundice"],"prefix":"10.3390","volume":"15","author":[{"given":"Chao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8565-928X","authenticated-orcid":false,"given":"Zijian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anatomy, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyou","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular, Jiang Xi Province Chest Hospital, Nanchang 330006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, X., She, Y., Kang, Q., and Chen, X. (2024). The clinical efficacy and safety of different biliary drainage in malignant obstructive jaundice: A meta-analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1370383"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/sjg.sjg_296_23","article-title":"Value of preoperative biliary drainage in pancreatic head cancer patients with severe obstructive jaundice: A multicenter retrospective study","volume":"30","author":"Lu","year":"2023","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40644-017-0129-1","article-title":"Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: A systematic review and meta-analysis","volume":"17","author":"Duan","year":"2017","journal-title":"Cancer Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/gutjnl-2024-333359","article-title":"Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"74","author":"Khan","year":"2025","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/0118715206313132240712101607","article-title":"Efficacy Analysis of PTCD + TACE vs. PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study","volume":"24","author":"Lu","year":"2024","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Huang, Q., Wang, F., Zhang, X., Liu, J., Dou, X., Feng, R., Zhu, K., Jiang, S., Zhang, Y., and Yue, J. (2023). Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11128-2"},{"key":"ref_9","first-page":"4665","article-title":"Effects of Different Palliative Jaundice Reducing Methods on Immunologic Functions in Patients with Advanced Malignant Obstructive Jaundice","volume":"37","author":"Tang","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","article-title":"Hepatitis B virus reactivation associated with anti-neoplastic therapy","volume":"28","author":"Yeo","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/jjco\/hyae105","article-title":"Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: A retrospective study","volume":"54","author":"Yin","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shen, J., Wang, X., Wang, N., Wen, S., Yang, G., Li, L., Fu, J., and Pan, X. (2023). HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1179689"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: A systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Elharabi, Z., Saba, J., and Akin, H. (2025). Navigating the Latest Hepatitis B Virus Reactivation Guidelines. Diseases, 13.","DOI":"10.3390\/diseases13110355"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12072-022-10450-4","article-title":"Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors","volume":"17","author":"Lei","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_19","first-page":"117","article-title":"Toll-like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: A case control study in Egyptian patients","volume":"23","author":"Elbrolosy","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3748\/wjg.v26.i30.4479","article-title":"High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure","volume":"26","author":"Zhou","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pan, S., Yu, Y., Wang, S., Tu, B., Shen, Y., Qiu, Q., Liu, X., Su, N., Zuo, Y., and Luan, J. (2022). Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.892618"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.14218\/JCTH.2023.00537","article-title":"Paclitaxel-induced Immune Dysfunction and Activation of Transcription Factor AP-1 Facilitate Hepatitis B Virus Replication","volume":"12","author":"Chen","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lazarevic, I., Banko, A., Miljanovic, D., and Cupic, M. (2019). Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses, 11.","DOI":"10.3390\/v11090778"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chang, Y., Jeong, S.W., and Jang, J.Y. (2022). Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front. Med., 8.","DOI":"10.3389\/fmed.2021.770124"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110199","DOI":"10.1016\/j.virol.2024.110199","article-title":"Ubiquitin: A double-edged sword in hepatitis B virus-induced hepatocellular carcinoma","volume":"599","author":"Kar","year":"2024","journal-title":"Virology"},{"key":"ref_26","unstructured":"Wang, L.Y. (2020). Clinical Study on Reactivation of Hepatitis B Virus After Hepatectomy, TACE and RFA for Hepatitis B-Related Liver Cancer, Shandong University."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:58:06Z","timestamp":1778061486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093263"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093263","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}